Zobrazeno 1 - 10
of 156
pro vyhledávání: ''
Publikováno v:
Frontiers in Pharmacology, Vol 15 (2024)
PurposeTo review current evidence on the efficacy and safety outcomes of HIF-PHIs in chronic kidney disease (CKD) populations with an emphasize on the safety profile.MethodsA systematic search was conducted in the Medline, Embase, and Cochrane Centra
Externí odkaz:
https://doaj.org/article/b40ef73de8474eda87457b1c7a875355
Autor:
Maxime Pluquet, Marie Metzger, Christian Jacquelinet, Christian Combe, Denis Fouque, Maurice Laville, Luc Frimat, Ziad A. Massy, Sophie Liabeuf, Solène M. Laville
Publikováno v:
Frontiers in Pharmacology, Vol 15 (2024)
Introduction: Adjusting drug dose levels based on equations that standardize the estimated glomerular filtration rate (eGFR) to a body surface area (BSA) of 1.73 m2 can pose challenges, especially for patients with extremely high or low body mass ind
Externí odkaz:
https://doaj.org/article/77673210426f4a55aed8fdda6559eb00
Publikováno v:
Frontiers in Pharmacology, Vol 15 (2024)
BackgroundStatins were regarded as a main medication for managing hypercholesterolemia. Administration of statin therapy could reduce the incidence of cardiovascular disease in individuals diagnosed with type 2 diabetes mellitus (DM), which was recog
Externí odkaz:
https://doaj.org/article/6afce17553a34b71968d03a2b2a5f838
Autor:
Mingying Zhang, Yubin Cai, Xiaoze Zhong, Weijun Liu, Yuan Lin, Zhanyi Qiu, Ruihuang Liang, Huibo Wei, Kefei Wu, Qinghua Liu
Publikováno v:
Frontiers in Pharmacology, Vol 15 (2024)
Kidney disease has become a global public health problem. Patients with end-stage kidney disease must rely on dialysis or undergo renal transplantation, placing heavy burdens on their families and society. Therefore, it is important to develop new th
Externí odkaz:
https://doaj.org/article/9dea6803405a41c4a689f2d15ab87698
Autor:
Hui-Fen Chen, Yu-Jie Lin, Yan Han, Xian-Long Zhang, Ruo-Bing Wang, Jun-Hui Chen, Ying Pi, Li-Zhe Fu, Fang Tang, Xi-Na Jie, Xiao-Na Tang, Xu-Sheng Liu, Yi-Fan Wu
Publikováno v:
Frontiers in Pharmacology, Vol 15 (2024)
BackgroundChinese patent medicine is commonly used in China as an important treatment mechanism to thwart the progression of chronic kidney disease (CKD) stages 3–5, among which Niaoduqing granules are a representative Chinese patent medicine; howe
Externí odkaz:
https://doaj.org/article/311d6546a006469bbaca230df8585cea
Publikováno v:
Frontiers in Pharmacology, Vol 15 (2024)
The Bailing Capsule is a commonly used traditional Chinese medicine for the treatment of chronic kidney disease (CKD). However, its therapeutic effects and pharmacological mechanisms have not been fully explored. In this study, we integrated meta-ana
Externí odkaz:
https://doaj.org/article/48fc07f81442439193cdd833f496c61d
Publikováno v:
Frontiers in Pharmacology, Vol 15 (2024)
Accumulating evidence suggests that hyperuricemia is a pathological factor in the development and progression of chronic kidney disease. However, the potential benefit afforded by the control of uric acid (UA) is controversial. Individual studies sho
Externí odkaz:
https://doaj.org/article/3b5f318955f648c8bee2a0960ed43e9a
Publikováno v:
Frontiers in Pharmacology, Vol 15 (2024)
Chronic kidney disease (CKD) is a progressive disorder characterized by structural and functional changes in the kidneys, providing a global health challenge with significant impacts on mortality rates. Extracellular vesicles (EVs), are vital in the
Externí odkaz:
https://doaj.org/article/e66cbbf24df744bc8907699e7502f586
Publikováno v:
Frontiers in Pharmacology, Vol 15 (2024)
Arachidonic acid (AA) is a main component of cell membrane lipids. AA is mainly metabolized by three enzymes: cyclooxygenase (COX), lipoxygenase (LOX) and cytochrome P450 (CYP450). Esterified AA is hydrolysed by phospholipase A2 into a free form that
Externí odkaz:
https://doaj.org/article/f9900b6d2492448882bedc4e2ce8965d
Autor:
Xueying Ding, Shujie Sun, Jinjin Zhang, Huifang Zhao, Fenglan Lun, Xuemin Liu, Yiwan Zhen, Jinping Dong, Jingliang Wu
Publikováno v:
Frontiers in Pharmacology, Vol 15 (2024)
Background: The application of ferric citrate therapy has yielded unexpected benefits in recent years for Chronic kidney disease patients suffering from hyperphosphatemia and iron deficiency -anaemia. Despite this, earlier research on the impact of f
Externí odkaz:
https://doaj.org/article/8561ca2440454439ab15a99f99d5055b